About Michael Dybbs
Michael Dybbs is a partner, samsara biocapital and director at Abcuro.
Michael Dybbs reports to the SEC as a director of 6 public companies, including Nkarta (NKTX), Sutro Biopharma (STRO) and Kalaris Therapeutics (KLRS).
Michael Dybbs first appears on SEC filings in 2014.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Dybbs in the role, so the role may have started earlier or lasted longer.
Abcuro, Inc.
Partner, Samsara BioCapital and director
2025 – 2026 · Newton, MA
Develops immunotherapies for people with autoimmune diseases and cancer.
NI
Nkarta, Inc.
Director
2020 – 2026 · Public company (NKTX)
SI
Sutro Biopharma, Inc.
Director
2018 – 2026 · Public company (STRO)
KI
Kalaris Therapeutics, Inc.
Director
2025 – 2026 · Public company (KLRS)
SI
DI
Dimension Therapeutics, Inc.
Director
2015 – 2017 · Public company (DMTX)
AI
Aravive, Inc.
Director
2014 · Public company (ARAV)
Key Colleagues at Startups
The people Michael Dybbs works with at each company, as listed on that company's latest Form D.
Abcuro, Inc. · Form D, Aug 13, 2026
JM
John Martin
Chief Executive Officer and director
RH
Ron Hunt
Director
Ming Fang
Managing Director, Redmile Group
Mark Pruzanski
Chairman of the Board
Sarah Boyce
Director